EP3615079A4 - Stabile cannabinoidformulierungen - Google Patents

Stabile cannabinoidformulierungen Download PDF

Info

Publication number: EP3615079A4
Authority: EP; European Patent Office
Prior art keywords: cannabinoid formulations; stable cannabinoid; stable; formulations; cannabinoid
Prior art date: 2017-04-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP17907335.8A

Other languages

English (en)

French (fr)

Other versions

EP3615079C0 (de

EP3615079A1 (de

EP3615079B1 (de

Inventor

Kiran Kumar VANGARA

Huaguang Li

Ningxin YAN

Hung Q. Nguyen

Venkat R. Goskonda

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Fresh Cut Development LLC

Original Assignee

Fresh Cut Development LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-04-27

Filing date

2017-09-22

Publication date

2020-09-23

2017-04-27 Priority claimed from US15/499,178 external-priority patent/US12544389B2/en

2017-09-22 Application filed by Fresh Cut Development LLC filed Critical Fresh Cut Development LLC

2017-09-22 Priority to EP25152261.1A priority Critical patent/EP4516355A3/de

2020-03-04 Publication of EP3615079A1 publication Critical patent/EP3615079A1/de

2020-09-23 Publication of EP3615079A4 publication Critical patent/EP3615079A4/de

2025-02-12 Application granted granted Critical

2025-02-12 Publication of EP3615079C0 publication Critical patent/EP3615079C0/de

2025-02-12 Publication of EP3615079B1 publication Critical patent/EP3615079B1/de

Status Active legal-status Critical Current

2037-09-22 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Child & Adolescent Psychology (AREA)
Physiology (AREA)
Pain & Pain Management (AREA)
Nutrition Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP17907335.8A 2017-04-27 2017-09-22 Stabile cannabinoidformulierungen Active EP3615079B1 (de)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP25152261.1A EP4516355A3 (de)	2017-04-27	2017-09-22	Stabile cannabinoidformulierungen

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15/499,178 US12544389B2 (en)	2014-05-29	2017-04-27	Stable cannabinoid formulations
PCT/US2017/052897 WO2018200024A1 (en)	2017-04-27	2017-09-22	Stable cannabinoid formulations

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
EP25152261.1A Division EP4516355A3 (de)	2017-04-27	2017-09-22	Stabile cannabinoidformulierungen

Publications (4)

Publication Number	Publication Date
EP3615079A1 EP3615079A1 (de)	2020-03-04
EP3615079A4 true EP3615079A4 (de)	2020-09-23
EP3615079C0 EP3615079C0 (de)	2025-02-12
EP3615079B1 EP3615079B1 (de)	2025-02-12

Family

ID=63920361

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP17907335.8A Active EP3615079B1 (de)	2017-04-27	2017-09-22	Stabile cannabinoidformulierungen
EP25152261.1A Pending EP4516355A3 (de)	2017-04-27	2017-09-22	Stabile cannabinoidformulierungen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP25152261.1A Pending EP4516355A3 (de)	2017-04-27	2017-09-22	Stabile cannabinoidformulierungen

Country Status (4)

Country	Link
EP (2)	EP3615079B1 (de)
JP (5)	JP2020517727A (de)
CA (1)	CA3062814C (de)
WO (1)	WO2018200024A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US12544389B2 (en)	2014-05-29	2026-02-10	Fresh Cut Development, Llc	Stable cannabinoid formulations
GB2530001B (en)	2014-06-17	2019-01-16	Gw Pharma Ltd	Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en)	2014-10-14	2016-04-20	Gw Pharma Ltd	Use of cannabinoids in the treatment of epilepsy
GB2539472A (en)	2015-06-17	2016-12-21	Gw Res Ltd	Use of cannabinoids in the treatment of epilepsy
JP2020517727A (ja) *	2017-04-27	2020-06-18	インシス・ディベロップメント・カンパニー・インコーポレイテッド	安定なカンナビノイド製剤
GB2568929A (en)	2017-12-01	2019-06-05	Gw Res Ltd	Use of cannabinoids in the treatment of epilepsy
WO2020123407A1 (en)	2018-12-11	2020-06-18	Disruption Labs Inc.	Compositions for the delivery of therapeutic agents and methods of use and making thereof
GB2584140A (en) *	2019-05-23	2020-11-25	Gw Res Ltd	Use of cannabidiol in the treatment of epileptic spasms
US20220347118A1 (en) *	2019-09-09	2022-11-03	Cardiol Therapeutics Inc.	Stable medicinal cannabidiol compositions
GB2588461A (en) *	2019-10-25	2021-04-28	Gw Res Ltd	Use of cannabidiol preparations in the treatment of absence epilepsy
US12642806B2 (en) *	2019-10-25	2026-06-02	Cardiol Therapeutics Inc.	Cannabidiol compositions for use in treating heart conditions
GB202009321D0 (en)	2020-06-18	2020-08-05	Gw Res Ltd	Use of cannabinoids in the treatment of epilepsy
AU2021347760B2 (en) *	2020-09-24	2024-07-25	Nicoventures Trading Limited	Formulation
TW202231192A (zh) *	2020-09-24	2022-08-16	英商尼可創業貿易有限公司	包裝調配物
JP2024528569A (ja) *	2021-07-13	2024-07-30	イーピーエム（アイピー），インコーポレイテッド	プラダー・ウィリー症候群を治療するためのカンナビジオール酸エステル
CN117813081A (zh) *	2021-07-13	2024-04-02	Epm(Ip)公司	用于治疗普拉德-威利综合征的大麻二醇酸酯
EP4376820A1 (de) *	2021-07-28	2024-06-05	GW Research Limited	Verwendung von cannabidiol zur behandlung von epilepsie
AU2023361756A1 (en) *	2022-10-12	2025-05-22	Leiutis Pharmaceuticals Llp	Novel liquid oral formulations of cannabidiol
CN116444351A (zh) *	2022-11-18	2023-07-18	中国人民解放军军事科学院军事医学研究院	一种核辐射损伤中对小肠有保护作用的天然小分子化合物
CN116172988A (zh) *	2022-11-18	2023-05-30	中国人民解放军军事科学院军事医学研究院	大麻二酚用于制备急性放射病的药物的用途
CN115887426A (zh) *	2022-11-18	2023-04-04	中国人民解放军军事科学院军事医学研究院	大麻二酚在制备核辐射损伤后骨髓恢复药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20150343071A1 (en) *	2014-05-29	2015-12-03	Insys Pharma, Inc.	Stable cannabinoid formulations
US20160271252A1 (en) *	2014-05-29	2016-09-22	Insys Development Company, Inc.	Stable cannabinoid formulations
WO2016191651A1 (en) *	2015-05-28	2016-12-01	Insys Development Company, Inc.	Stable cannabinoid formulations
US20160367496A1 (en) *	2014-05-29	2016-12-22	Insys Development Company, Inc.	Stable cannabinoid formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0514060A (pt) *	2004-08-03	2008-05-27	Orexigen Therapeutics Inc	combinação de bupropion e um segundo composto para acarretar a perda de peso
NZ568400A (en) *	2005-11-23	2011-11-25	Ironwood Pharmaceuticals Inc	Methods and compositions for the treatment of gastrointestinal disorders
GB2438682A (en) *	2006-06-01	2007-12-05	Gw Pharma Ltd	New use for cannabinoids
US20110262442A1 (en) *	2009-11-06	2011-10-27	Adenios, Inc.	Compositions for treating cns disorders
US20130210821A1 (en) *	2010-05-27	2013-08-15	James E. Vath	Methods for Treating Obesity
US11331279B2 (en)	2014-05-29	2022-05-17	Radius Pharmaceuticals, Inc.	Stable cannabinoid formulations
JP2020517727A (ja) *	2017-04-27	2020-06-18	インシス・ディベロップメント・カンパニー・インコーポレイテッド	安定なカンナビノイド製剤

2017
- 2017-09-22 JP JP2019558668A patent/JP2020517727A/ja active Pending
- 2017-09-22 EP EP17907335.8A patent/EP3615079B1/de active Active
- 2017-09-22 WO PCT/US2017/052897 patent/WO2018200024A1/en not_active Ceased
- 2017-09-22 CA CA3062814A patent/CA3062814C/en active Active
- 2017-09-22 EP EP25152261.1A patent/EP4516355A3/de active Pending
2022
- 2022-06-01 JP JP2022089421A patent/JP2022130390A/ja active Pending
2024
- 2024-07-16 JP JP2024113145A patent/JP2024161363A/ja active Pending
2025
- 2025-05-07 JP JP2025077149A patent/JP2025118787A/ja active Pending
- 2025-05-07 JP JP2025077148A patent/JP2025118786A/ja active Pending

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20150343071A1 (en) *	2014-05-29	2015-12-03	Insys Pharma, Inc.	Stable cannabinoid formulations
US20160271252A1 (en) *	2014-05-29	2016-09-22	Insys Development Company, Inc.	Stable cannabinoid formulations
US20160367496A1 (en) *	2014-05-29	2016-12-22	Insys Development Company, Inc.	Stable cannabinoid formulations
WO2016191651A1 (en) *	2015-05-28	2016-12-01	Insys Development Company, Inc.	Stable cannabinoid formulations

Also Published As

Publication number	Publication date
EP3615079C0 (de)	2025-02-12
EP3615079A1 (de)	2020-03-04
JP2024161363A (ja)	2024-11-19
JP2025118786A (ja)	2025-08-13
JP2020517727A (ja)	2020-06-18
WO2018200024A1 (en)	2018-11-01
CA3062814A1 (en)	2018-11-01
EP4516355A3 (de)	2025-05-28
EP3615079B1 (de)	2025-02-12
CA3062814C (en)	2023-11-14
JP2025118787A (ja)	2025-08-13
JP2022130390A (ja)	2022-09-06
EP4516355A2 (de)	2025-03-05

Legal Events

Date	Code	Title	Description
2018-11-02	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2020-01-31	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2020-01-31	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2020-03-04	17P	Request for examination filed	Effective date: 20191126
2020-03-04	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2020-03-04	AX	Request for extension of the european patent	Extension state: BA ME
2020-05-06	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: FRESH CUT DEVELOPMENT, LLC
2020-08-05	DAV	Request for validation of the european patent (deleted)
2020-08-05	DAX	Request for extension of the european patent (deleted)
2020-08-12	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: FRESH CUT DEVELOPMENT, LLC
2020-09-23	A4	Supplementary search report drawn up and despatched	Effective date: 20200826
2020-09-23	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 47/10 20170101ALI20200820BHEP Ipc: A61P 3/00 20060101ALI20200820BHEP Ipc: A61K 47/14 20170101AFI20200820BHEP Ipc: A61P 25/08 20060101ALI20200820BHEP Ipc: A61K 47/44 20170101ALI20200820BHEP Ipc: A61P 3/04 20060101ALI20200820BHEP Ipc: A61K 31/05 20060101ALI20200820BHEP
2022-07-29	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2022-08-31	17Q	First examination report despatched	Effective date: 20220802
2023-03-06	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2023-03-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2023-04-05	INTG	Intention to grant announced	Effective date: 20230307
2023-04-19	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: RADIUS PHARMACEUTICALS, INC.
2023-06-21	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230517
2023-10-18	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2023-10-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2023-11-22	INTC	Intention to grant announced (deleted)
2023-12-19	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2023-12-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2024-01-17	INTG	Intention to grant announced	Effective date: 20231220
2024-07-15	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2024-07-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2024-08-21	INTC	Intention to grant announced (deleted)
2024-08-29	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2024-08-29	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2024-10-02	INTG	Intention to grant announced	Effective date: 20240830
2024-11-27	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: FRESH CUT DEVELOPMENT, LLC
2025-01-02	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2025-01-10	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2025-01-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2025-02-12	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2025-02-12	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2025-02-14	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2025-02-27	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602017087772 Country of ref document: DE
2025-03-12	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2025-04-16	U01	Request for unitary effect filed	Effective date: 20250312
2025-04-23	P04	Withdrawal of opt-out of the competence of the unified patent court (upc) registered	Free format text: CASE NUMBER: APP_13438/2025 Effective date: 20250318
2025-04-23	U07	Unitary effect registered	Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI Effective date: 20250321
2025-07-07	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250512
2025-07-09	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250212
2025-07-10	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250212
2025-07-14	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250612 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250512
2025-07-16	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250212
2025-07-21	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250513
2025-10-06	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250212
2025-10-08	U20	Renewal fee for the european patent with unitary effect paid	Year of fee payment: 9 Effective date: 20250902
2025-10-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20250704 Year of fee payment: 9
2025-10-22	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250212
2025-10-27	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250212
2025-12-19	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2025-12-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2025-12-24	REG	Reference to a national code	Ref country code: CH Ref legal event code: L10 Free format text: ST27 STATUS EVENT CODE: U-0-0-L10-L00 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20251224
2026-01-21	26N	No opposition filed	Effective date: 20251113
2026-05-04	REG	Reference to a national code	Ref country code: CH Ref legal event code: H13 Free format text: ST27 STATUS EVENT CODE: U-0-0-H10-H13 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20260504
2026-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250212
2026-07-16	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20250930 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20250922

Publication	Publication Date	Title
IL289084A (en)	2022-02-01	Cannabinoid formulations
DK3302437T3 (da)	2023-01-09	Stabile cannabinoidformuleringer
IL288423A (en)	2022-01-01	Cannabinoid formulations
IL268697A (en)	2019-10-31	Formulations
DK3688162T3 (da)	2024-05-13	Formuleringer
EP3148589C0 (de)	2024-10-30	Stabile cannabinoidformulierungen
EP3703672A4 (de)	2021-12-01	Cannabinoidformulierungen
EP3615079C0 (de)	2025-02-12	Stabile cannabinoidformulierungen
EP3642262A4 (de)	2020-05-06	Härtbare polyimide
MA50657A (fr)	2020-08-05	Formulations de niraparib
EP3641726C0 (de)	2025-11-05	Cannabinoid-beutel
EP3574547C0 (de)	2023-08-16	Wellenleiteranordnung
EP3462885A4 (de)	2020-01-22	Stabile cannabinoidformulierungen
EP3645897A4 (de)	2021-02-17	Lager
EP3367997A4 (de)	2019-07-03	Neuartige okklusive formulierungen
PL3703518T3 (pl)	2024-11-12	Formulacja ulegająca aerozolowaniu
EP3646858A4 (de)	2020-05-27	Verkapselte formulierungen
EP3364945C0 (de)	2024-12-04	Feste formulierungen
DK3651736T3 (da)	2021-09-27	Langtidsvirkende formuleringer
EP3612761C0 (de)	2023-12-13	Koppler
EP3585412A4 (de)	2020-12-09	Stabile peptidzusammensetzungen
IT201700051935A1 (it)	2018-11-12	Dispositivo laser
EP3437579C0 (de)	2023-07-12	Kryochirurgisches instrument
HUE063178T2 (hu)	2023-12-28	Kopanlizib formulációi
EP3683000A4 (de)	2020-11-18	Laservorrichtung